2,166 results on '"Mann, Douglas"'
Search Results
2. Defining cardiac functional recovery in end-stage heart failure at single-cell resolution
3. Proteomic Associations of NT-proBNP (N-Terminal Pro-B-Type Natriuretic Peptide) in Heart Failure With Preserved Ejection Fraction
4. Pulmonary Congestion and Left Ventricular Dysfunction After Myocardial Infarction: Insights From the PARADISE-MI Trial
5. Recurrent Adrenergic Stress Provokes Persistent Myocarditis in PD-1–Deficient Mice
6. Abstract 18200: Prognostic Importance of Serial NT-proBNP Measurements Following High-Risk Mi: The PARADISE-MI Trial
7. Abstract 14399: Development of Heart Failure in High-Risk Post-Myocardial Infarction Patients: An Analysis of the Paradise-MI Trial
8. Abstract 12972: Trained Innate Immunity Through Toll-Like Receptor 4/Interferon Signaling Establishes Cardioprotection in a Stress-Induced Cardiomyopathy Model
9. Abstract 12701: Safety and Tolerability of Angiotensin Receptor Neprilysin Inhibitor Initiation in High-Risk Acute Myocardial Infarction Relative to Drug Initiation Setting: A Subgroup Analysis of the PARADISE-MI Trial
10. Recurrent Myocardial Injury Leads to Disease Tolerance in a Murine Model of Stress-Induced Cardiomyopathy
11. Foreword
12. LNG measurement : a user's guide for custody transfer
13. The thermodynamic properties of helium from 3 to 300* K between 0.5 and 100 atmospheres
14. Comparison of symptomatic and functional responses to vagus nerve stimulation in ANTHEM‐HF, INOVATE‐HF, and NECTAR‐HF
15. Cognitive Decline Over Time in Patients With Systolic Heart Failure Insights From WARCEF
16. Distinct Inflammatory Milieu in Patients With Right Heart Failure
17. Safety and Tolerability of Angiotensin Receptor-Neprilysin Inhibitor Initiation in High-Risk Acute Myocardial Infarction Relative to Care Setting: A Subgroup Analysis of the PARADISE-MI Trial
18. The Emerging Field of Cardioimmunology: Past, Present and Foreseeable Future
19. Recognizing Early Career Translational Investigators
20. Targeting the Autophagy-Lysosome Pathway in a Pathophysiologically Relevant Murine Model of Reversible Heart Failure
21. The Programmed Death-1 Signaling Axis Modulates Inflammation and LV Structure/Function in a Stress-Induced Cardiomyopathy Model
22. Association between mortality and implantable cardioverter‐defibrillators by aetiology of heart failure: a propensity‐matched analysis of the WARCEF trial
23. Left atrial volume and cardiovascular outcomes in systolic heart failure: effect of antithrombotic treatment
24. Tolerability of Sacubitril/Valsartan in Patients With Advanced Heart Failure: Analysis of the LIFE Trial Run-In
25. Frailty Measures of Patient-reported Activity and Fatigue May Predict 1-year Outcomes in Ambulatory Advanced Heart Failure: A Report From the REVIVAL Registry
26. TRAF2, an Innate Immune Sensor, Reciprocally Regulates Mitophagy and Inflammation to Maintain Cardiac Myocyte Homeostasis
27. Proteomic Correlates and Prognostic Significance of Kidney Injury in Heart Failure With Preserved Ejection Fraction.
28. Prognostic Significance and Biologic Associations of Senescence-Associated Secretory Phenotype Biomarkers in Heart Failure.
29. Heart Failure Severity and Quality of Warfarin Anticoagulation Control (From the WARCEF Trial)
30. Proteomic Associations of Adverse Outcomes in Human Heart Failure
31. Should All Translational Scientists Be Swifties?
32. Proteomic Correlates And Prognostic Significance Of Kidney Injury In Heart Failure With Preserved Ejection Fraction
33. JACC: Basic to Translational Science Top Reviewers 2023: With Appreciation and Gratitude
34. Autonomic Regulation Therapy To Improve Symptoms And Clinical Outcomes In Patients With Heart Failure And Reduced Ejection Fraction (ANTHEM-HFrEF) Pivotal Study Results
35. The Effects of Angiotensin Receptor-Neprilysin Inhibition on Major Coronary Events in Patients With Acute Myocardial Infarction: Insights From the PARADISE-MI Trial
36. Predictive Value of Cardiopulmonary Exercise Testing Parameters in Ambulatory Advanced Heart Failure
37. Aspirin Does Not Increase Heart Failure Events in Heart Failure Patients From the WARCEF Trial
38. Resting Heart Rate and Ischemic Stroke in Patients with Heart Failure
39. Associations of methyl donor and methylation inhibitor levels during anti-oxidant therapy in heart failure
40. CHA2DS2‐VASc score and adverse outcomes in patients with heart failure with reduced ejection fraction and sinus rhythm
41. Sacubitril/Valsartan in Advanced Heart Failure With Reduced Ejection Fraction: Rationale and Design of the LIFE Trial
42. COVID-19 Clinical Trials: A Primer for the Cardiovascular and Cardio-Oncology Communities
43. Impact of Socioeconomic Factors on Patient Desire for Early LVAD Therapy Prior to Inotrope Dependence
44. Quality of life and treatment preference for ventricular assist device therapy in ambulatory advanced heart failure: A report from the REVIVAL study
45. INTERMACS profiles and outcomes of ambulatory advanced heart failure patients: A report from the REVIVAL Registry
46. Registry Evaluation of Vital Information for VADs in Ambulatory Life (REVIVAL): Rationale, design, baseline characteristics, and inclusion criteria performance
47. Targeting Inflammation in Pulmonary Artery Hypertension: Is It Time to Forget About the Lungs?
48. Left Ventricular Ejection Fraction and Risk of Stroke and Cardiac Events in Heart Failure
49. Emerging Research Directions in Adult Congenital Heart Disease A Report From an NHLBI/ACHA Working Group
50. Sacubitril/valsartan compared to ramipril in high‐risk post‐myocardial infarction patients stratified according to use of mineralocorticoid receptor antagonists: insight from the PARADISE MI trial
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.